Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

Int J Biol Sci. 2020 Mar 15;16(10):1718-1723. doi: 10.7150/ijbs.45123. eCollection 2020.


A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.

Keywords: COVID-19; Neutralizing antibody; SARS-CoV-2; severe acute respiratory syndrome.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adaptive Immunity
  • Antibodies, Neutralizing / therapeutic use*
  • Antibodies, Viral / therapeutic use*
  • Antiviral Agents
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Serotherapy
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy*
  • Humans
  • Immunity, Innate
  • Immunization, Passive
  • Pandemics
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2
  • Severe acute respiratory syndrome-related coronavirus


  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antiviral Agents